Royalty Report: Drugs, Diagnostic, Disease – Collection: 245871


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Diagnostic
  • Disease
  • Biotechnology
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 245871

License Grant
Licensor hereby grants to Israeli Licensee a world-wide, exclusive license, with the right to sublicense within the Field, under the Licensor Technology to make ribozymes only for research purposes and to develop, use, make and have made and sell Semi-finished Products, Products or perform Licensed Services against Target Diseases provided, however, Licensee shall have the right to sell Semi-finish Products only to Corporate Partners which have entered into a sublicense with Licensee. Licensees right to make or have made Semi-finished Products, Products and perform Licensed Services shall be subject at all times to Licensors exclusive right to manufacture and supply Ribozymes for those purposes. Nothing contained herein shall be construed as granting a license, implied or otherwise, to Licensee or any third party to manufacture Ribozymes using the Licensor technology except under the conditions and as specifically set forth.
License Property
Licensor Technology shall mean
US 4,987,071 – RNA Ribozyme Polymerases, Dephosphorylases, Restriction Endoribonucleases and Methods
US 5,037,746 – RNA Ribozyme Polymerases and Methods
US 5,093,246 – RNA Ribozyme Polymerases, Dephosphorylases, Restriction Endoribonucleases and Methods

Ribozyme shall mean a nucleic acid molecule capable of catalyzing reactions including, but not limited to, site-specific cleavage and/or ligation of other nucleic acid molecules, cleavage of peptide and amide bonds, polymerization and transsplicing.

Ribozymes For Research shall mean Ribozymes required by Licensee for purposes of research and development of a Semi-finished Product, Product or Licensed Service, including those required under a Work Plan approved by Licensor.

Ribozymes For Products shall mean Ribozymes used in Semi-finished Products, Products or Licensed Services.

Product shall mean products designed, developed, and sold against a Target Disease by Licensee (or Licensor in the event of a reversion), or an Affiliate, Collaborator or Corporate Partner and which is generally in finished form and ready for end use without further substantial chemical alteration.

Licensed Services shall mean any service within the Field, other than the development, production and sale of a Product or Semi-finished Product, which is performed for a third-party by Licensee, an Affiliate or a sublicensee hereunder, and which includes use of a Semi-finished Product or Product or any invention, method, process, procedure or technology which is included, in whole or in part, in Licensor Technology.

Target Disease shall mean any one of the human diseases conditions for which a Work Plan has been approved by Licensor.

Semi-finished Product shall mean ribozymes or products which have not been substantially transformed by Licensee or an Affiliate into a Product and which are transferred to a Corporate Partner in an arms length transaction for the purpose of sales of Products and/or Licensed Services.

Field of Use
Field shall mean in vitro diagnostics for the diagnosis of Target Disease using Ribozymes in Amplified Nucleic Acid Formats.

IPSCIO Record ID: 203505

License Grant
After completing Phase I Clinical Trials, Licensee has decided to repurchase all rights to the Ribozyme Product.
License Property
The Ribozyme Products rights are to Heptazyme(TM), an Anti-Hepatitis C ribozyme, and all other Hepatitis C ribozyme products.
Field of Use
This agreement is for use on Hepatitis C.

IPSCIO Record ID: 27234

License Grant
Licensee entered into that certain License Agreement with the University pertaining to an invention entitled, External Guide Sequences for an RNA Enzyme.
License Property
One of these core technologies is designed to utilize Innovir's proprietary EGS ('External Guide Sequence') Oligozyme technology to direct a cellular ribozyme to disease-causing RNA, so that the ribozyme will cleave the RNA and thus render it inactive. An EGS Oligozyme is a small, chemically modified oligonucleotide segment that binds to a disease-causing RNA to create a structure resembling a type of RNA which is cleaved by a specific ribozyme in cells. This naturally occurring cellular ribozyme, called RNase P, has been harnessed to cleave such newly formed structures, thereby destroying the disease-causing RNA molecules before they can be used to create disease-causing proteins.

Patent No. 5,168,053

Field of Use
The rights granted apply to the Licensed Patents.

IPSCIO Record ID: 211894

License Grant
The German Licensor grants the Israeli Licensee a co-exclusive, worldwide, royalty-bearing license under the Licensed Patent Rights to develop, have developed, make, have made, use, have used, import, have imported, sell and have sold Licensed Products, and to perform, have performed, sell and have sold Licensed Services, each in the Field.

In order to establish co-exclusivity, Licensor shall not grant, during the Term, more than three other co-exclusive licenses to the Licensed Patent Rights in the Field with the scope of Other Diagnostic Licenses, or the Other Diagnostic Licensees.

Licensee shall have the right to grant sublicenses.

License Property
Diagnostic kits shall be considered as Licensed Products.

The Platform Technologies shall mean any technology for qualitative and/or quantitative detection or quantification of nucleic acids and genotyping used in the performance of a Licensed Service or offered as part of a Licensed Product, including, without limitation, RNA extraction and/or PCR technologies, including, without limitation, realtime based, microarray technologies, or any current or future technology providing substantially similar any means.

Patents filed are for Small expressed RNA molecules (MicroRNA molecules).

Analyte Specific Reagents or ASRs shall mean antibodies, both polyclonal and monoclonal, specific receptor proteins, ligands, nucleic acid sequences, and similar reagents which, through specific binding or chemical reaction with substances in a specimen, are intended for use in a diagnostic application for identification and quantification of an individual chemical substance or ligand in biological specimens. ASRs that otherwise fall within this definition shall not fall within this definition when they are sold to in vitro diagnostic manufacturers for the purpose of manufacturing in vitro diagnostic products, or organizations that use the reagents to make tests for purposes other than providing diagnostic information to patients and practitioners, e.g., forensic, academic, research, and other non-clinical laboratories.

Field of Use
The Field shall mean sale and use of Licensed Products, or performance and sale of Licensed Services, for Licensees internal and collaborative research and development purposes, and Diagnostic Purposes, specifically excluding any sale and use of Licensed Products, or performance and sale of Licensed Services, for Research Purposes or for Therapeutic Purposes.  This agreement is to develop and commercialize products and services for Diagnostic Purposes.

The licensed microRNAs sequences will be added to Licensee microRNA database, providing the company with additional biomarker candidates for its diagnostic development programs.  Under the terms of the agreement, Licensee will be able to use these microRNAs to advance multiple research and development programs targeting new microRNA-based diagnostic tools for a variety of diseases.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.